Project Grant R44DK148299
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Trustees of Boston University $791,614 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an artificial intelligence–driven digital pathology platform for kidney disease diagnosis and research. The recipient will build foundational deep learning models capable of automated segmentation, quantification, and disease classification from...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $784,606 on August 25, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop highly multiplexed volumetric light sheet microscopy for thick tissue imaging. The award funds development of an innovative platform combining light-sheet microscopy with high-multiplex fluorescence imaging capable of up to approximately 35-plex imaging using...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Immunowork LLC $304,993 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate a flow cytometry-based biomarker assay quantifying circulating PLA2R antigen-specific memory B cells in patients with primary membranous nephropathy. The assay detects PLA2R-MBCs, the cellular precursor of anti-PLA2R autoantibody production, to predict...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded In Vivo Microsystems Technologies, LLC $3,067,867 on September 19, 2025, for a Phase 2 Small Business Innovation Research project under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). IVMT will conduct a Phase 2 multi-center in-vivo study of a near-infrared fluorescently-labeled peptide heterodimer targeting EGFR and ERBB2 for detection of biliary intra-epithelial neoplasia. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $810,834 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Assistance Listing Project Grant R01DK145010). The award funds an ancillary study that integrates advanced retinal imaging into the Kidney Precision Medicine Project, a national NIDDK-funded cohort study of people with diabetes and/or hypertension. The research aims...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded a Cooperative Agreement totaling $611,688 to Weill Medical College of Cornell University on September 12, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an AI-based image phenotyping core for autosomal dominant polycystic kidney disease (ADPKD) research. The recipient will establish a biomedical research core that comprehensively labels and annotates...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Boston University Medical Campus a $478,011 Project Grant (CFDA 93.847: Diabetes, Digestive, and Kidney Diseases Extramural Research) on September 11, 2025, with completion anticipated by August 31, 2027. This grant funds development of an automated deep learning platform specifically designed to analyze transmission electron microscopy (TEM) images of kidney tissue. The platform...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $816,825 on April 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how injured podocytes communicate with parietal epithelial cells to drive proliferative glomerulopathy, specifically whether podocyte-derived exosomes mediate this cell-to-cell signaling in rapidly progressive glomerulonephritis. The research uses...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $388,750 on April 23, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the structural and functional mechanisms of podocin in glomerular membrane organization and kidney disease. The research applies detergent-free, vesicle-based cryo-electron microscopy to determine the full-length structure of podocin at near-atomic resolution...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Kscube, LLC $315,335 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a real-time, non-invasive urinary oxygen monitoring system for acute kidney injury prevention. The recipient will advance development of a novel continuous kidney-stress monitor for use during surgery and in intensive care units. The technology provides real-time detection of...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Panluminate Inc. $354,958 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate the PAN-EXM Renal Pathology Platform, an AI-enabled diagnostic system for podocytopathies including focal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease. Panluminate will deliver three core products over the 30-month period of performance ending May 31, 2029: diagnostic validation of pan-expansion microscopy (PAN-EXM) against gold-standard assays in 100 archived kidney biopsies; engineering and prototyping of a clinic-ready benchtop instrument that automates tissue expansion, labeling, and light-sheet imaging; and integration of a supervised AI model trained on validation data to provide real-time classification and severity scoring for renal pathology interpretation. The platform consolidates three separate assays (light microscopy, immunofluorescence, and electron microscopy) into a single multiplexed biomarker imaging and ultrastructural assessment workflow to reduce diagnostic turnaround time and cost. Work is performed in Connecticut. Panluminate Inc., a woman-owned small business headquartered in New Haven, Connecticut, specializes in advanced microscopy and spatial biology technologies and has received prior federal support from multiple NIH institutes for imaging technology development.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $355.0k | 7/30/26 |